Loading market dashboard
Insmed Incorporated
INSMHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees.
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m.
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended to provide “anchor points” around what he described as “one of the strongest launches in recent years.
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.
Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis Symptoms Often Overlap with COPD or Asthma and May Go Unrecognized for Years, Highlighting the Need to Look Deeper at Respiratory Symptoms — — TV Personality, Ty Pennington, Brings Visibility to the Chronic Lung Condition Through His Experience Caring for His Mother, Who is Living with Bronchiectasis — BRIDGEWATER, N.J., May 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced a collaboration with Emmy® Award–winning TV host, designer, and carpenter, Ty Pennington, to launch Suspect Bronchiectasis (Suspect BE).
—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprostinil Palmitil Inhalation Powder Phase 3 Development Program— —Additionally, Insmed Provides Independent Research Grant to the American Thoracic Society for a Landmark Quality Initiative to Improve Diagnosis of Bronchiectasis across the U.S.— BRIDGEWATER, N.J., May 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present six abstracts from across its respiratory portfolio and pipeline at the American Thoracic Society International Conference 2026 (ATS 2026), taking place May 17–20 in Orlando, Florida.
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026, at 1:40 p.m.
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its first-quarter 2026 financial results on Thursday, May 7, 2026.
GraniteShares Advisors LLC purchased a new position in shares of Insmed, Inc. (NASDAQ: INSM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,905 shares of the biopharmaceutical company's stock, valued at approximately $680,000. A number of other large investors also recently
Asset Management One Co. Ltd. acquired a new position in shares of Insmed, Inc. (NASDAQ: INSM) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 80,887 shares of the biopharmaceutical company's stock, valued at approximately $14,260,000. A number of other hedge
Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Insmed, Inc. (NASDAQ: INSM) by 764.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,492 shares of the biopharmaceutical company's stock after acquiring an additional 69,410
Assetmark Inc. boosted its holdings in Insmed, Inc. (NASDAQ: INSM) by 12.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,732 shares of the biopharmaceutical company's stock after buying an additional 4,438 shares during the period. Assetmark Inc.'s
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.
Park Capital Management LLC WI acquired a new position in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,989 shares of the biopharmaceutical company's stock, valued at approximately $1,042,000. Insmed comprises approximately
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued
Allspring Global Investments Holdings LLC lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 3.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 220,084 shares of the biopharmaceutical company's stock after selling 7,545 shares during the period.
Insmed Inc (NASDAQ:INSM) shares were last seen up 0.3% to trade at $164.03, after a price-target hike to $237 from $231 at Barclays.
Insmed remains a Buy, with enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Brinsupri's launch exceeded expectations, with Q4 revenues of $144.6M and management guiding for $1B in 2026 sales. TPIP offers differentiation in PAH/PH-ILD with once-daily dosing and encouraging Phase 2b data, supporting a $3B rNPV estimate.
Insmed (INSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
E. Ohman J or Asset Management AB purchased a new stake in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,239 shares of the biopharmaceutical company's stock, valued at approximately $912,000. Other hedge funds and other institutional investors
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States.
Insmed (INSM) remains a "Strong Buy", driven by positive phase 3b ENCORE results for ARIKAYCE in 1st-line MAC lung disease and robust pipeline progress. INSM is positioned to expand ARIKAYCE's label to 1st-line MAC patients [200k+], convert accelerated to full approval for refractory MAC, and pursue Japanese label expansion. BRINSUPRI is approved for non-cystic fibrosis bronchiectasis, with 2026 revenue guidance of at least $1 billion; ARIKAYCE 2025 sales reached $433.8 million, up 19% YoY.
Insmed stock jumps as Arikayce meets key goals in a late-stage study, paving the way for label expansion and a major boost to its potential market.
Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript
The ENCORE study's results indicate that Arikayce (amikacin liposome inhalation suspension), in combination with a multidrug therapy, met its primary and all secondary endpoints, showcasing its potential to benefit patients with Mycobacterium avium complex lung infections.
Insmed Incorporated (NASDAQ:INSM) shares jumped almost 8% in early trade on Monday after the company reported positive topline results from a Phase 3b study evaluating its lung disease therapy ARIKAYCE. The ENCORE trial assessed ARIKAYCE (amikacin liposome inhalation suspension) in combination with standard multidrug therapy versus placebo plus multidrug therapy in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection who had not previously received antibiotics.
—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rates— —In the Second Half of 2026, Insmed Plans to File a Supplemental NDA for ARIKAYCE with the FDA and Submit the Data to the PMDA in Japan to Support Potential Label Changes— —Insmed to Host Investor Conference Call on Monday, March 23, 2026, at 8:00 AM ET— BRIDGEWATER, N.J., March 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced positive topline results from the Phase 3b ENCORE study.
Bank of Nova Scotia purchased a new stake in shares of Insmed, Inc. (NASDAQ: INSM) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 506,245 shares of the biopharmaceutical company's stock, valued at approximately $72,904,000. Bank of
Aquatic Capital Management LLC trimmed its stake in Insmed, Inc. (NASDAQ: INSM) by 61.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 76,343 shares of the biopharmaceutical company's stock after selling 123,591 shares during the quarter. Aquatic Capital Management LLC's
Algert Global LLC boosted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 76.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 144,726 shares of the biopharmaceutical company's stock after acquiring an additional 62,802 shares during the period. Algert
Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript
Insmed, Inc. (NASDAQ: INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the company's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $146.03, for a total value of $1,562,374.97. Following the sale, the chief executive officer owned 301,185 shares of the company's stock, valued
